GSE136157 Microarray analysis of ErbB2-driven mouse mammary tumour cells treated with GSK-126

Contributors : Alison Hirukawa ; William J MullerSeries Type : Expression profiling by arrayOrganism : Mus musculusMonoclonal antibodies (mAbs) targeting the oncogenic receptor tyrosine kinase ERBB2/HER2, such as Trastuzumab, are the standard of care therapy for breast cancers driven by ERBB2 overexpression and activation. However, a substantial proportion of patients exhibits de novo resistance. Here, by comparing matched Trastuzumab-na ïve and post-treatment patient samples from a neoadjuvant trial, we link resistance with elevation of H3K27me3, a repressive histone modification catalyzed by Polycomb Repressor Complex 2 (PRC2). In ErbB2+ breast cancer models, PRC2 silences endogenous retroviruses (ERVs) to suppress anti-tumor Typ e-I interferon (IFN) responses. In patients, elevated H3K27me3 in tumor cells following Trastuzumab treatment correlates with suppression of IFN-driven viral defense gene expression signatures and poor response. Using an immunocompetent model, we provide evidence that EZH2 inhibitors promote IFN-dri ven immune responses that enhance the efficacy of anti-ErbB2 mAbs, suggesting the potential clinical benefit of epigenomic reprogramming by H3K27me3 depletion in Trastuzumab-resistant disease.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research

Related Links:

Abstract PURPOSE: High levels of tumor-infiltrating lymphocytes (TILs) before neoadjuvant chemotherapy (NAC) are associated with higher pathological complete response (pCR) rates, and better survival in TNBC and HER2-positive breast cancers (BCs). We investigated the value of TIL levels by evaluating lymphocyte infiltration before and after NAC. PATIENTS AND METHODS: We assessed stromal TIL levels in 716 pre- and post-treatment matched paired specimens, according to the guidelines of the international TIL working group. RESULTS: Pre-NAC TIL levels were higher in tumors for which pCR was achieved than in ...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Authors: Mangone L, Mancuso P, Tagliabue G, Filiberti RA, Carrozzi G, Iacovacci S, Mazzucco W, Tumino R, Minicozzi P, Sant M, Giorgi Rossi P Abstract OBJECTIVE: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I-III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. METHODS: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009-2013). Included were 3546 women aged
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
ConclusionDespite guideline recommendations, a high rate of preoperative staging imaging is completed for patients with clinical stage 1 or 2 breast cancer who receive NAC, with few positive results.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThese results showed that changes in ser-miR-21 levels were significantly related to NCCT clinical response and prognosis. Ser-miR-21 may serve as a non-invasive biomarker to predict NCCT response in HER2-positive breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Contributors : Alison Hirukawa ; Willliam Muller ; Jarey WangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMonoclonal antibodies (mAbs) targeting the oncogenic receptor tyrosine kinase ERBB2/HER2, such as Trastuzumab, are the standard of care therapy for breast cancers driven by ERBB2 overexpression and activation. However, a substantial proportion of patients exhibits de novo resistance. Here, by comparing matched Trastuzumab-na ïve and post-treatment patient samples from a neoadjuvant trial, we link resistance with elevation of H3K27me3, a repressive histone modification cata...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Condition:   Breast Cancer Interventions:   Drug: Pyrotinib;   Drug: nab-Paclitaxel;   Drug: Trastuzumab;   Drug: EC chemotherapy;   Procedure: Surgery Sponsors:   Shanghai Jiao Tong University School of Medicine;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: Collagen degradation markers are associated with response to neoadjuvant therapy and seem to play a role in breast cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | Neoadjuvant Therapy